Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Oncopeptides AB ( (SE:ONCO) ).
Oncopeptides AB has announced the publication of real-world evidence abstracts on its drug Pepaxti, presented at the International Myeloma Society Annual Meeting. The studies from Spain and Italy confirm Pepaxti’s efficacy and safety in treating relapsed or refractory multiple myeloma, even in heavily pretreated patients. The results highlight Pepaxti’s effectiveness and tolerability, providing valuable insights for clinicians and payers in making treatment decisions based on real-world evidence.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. Utilizing its proprietary Peptide Drug Conjugate platform, the company develops compounds that selectively deliver cytotoxic agents into cancer cells. Oncopeptides’ flagship drug, Pepaxti, is being commercialized in Europe, with partnerships in South Korea, the Middle East, and Africa. Founded in 2000, Oncopeptides has approximately 80 employees and operates in several European countries.
Average Trading Volume: 5,817,299
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.29B
See more insights into ONCO stock on TipRanks’ Stock Analysis page.